These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22768185)

  • 1. High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity.
    Kumar A; Zhang M; Zhu L; Liao RP; Mutai C; Hafsat S; Sherman DR; Wang MW
    PLoS One; 2012; 7(6):e39961. PubMed ID: 22768185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency boost of a
    Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
    Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
    Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
    Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
    Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
    Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
    Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
    Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
    Sharma K; Tanwar O; Deora GS; Ali S; Alam MM; Zaman MS; Krishna VS; Sriram D; Akhter M
    Bioorg Med Chem; 2019 Apr; 27(7):1421-1429. PubMed ID: 30827867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological validation of dihydrofolate reductase as a drug target in
    Aragaw WW; Negatu DA; Bungard CJ; Dartois VA; Marrouni AE; Nickbarg EB; Olsen DB; Warrass R; Dick T
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0071723. PubMed ID: 38018963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
    Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
    Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
    Yang X; Wedajo W; Yamada Y; Dahlroth SL; Neo JJ; Dick T; Chui WK
    Eur J Med Chem; 2018 Jan; 144():262-276. PubMed ID: 29274493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
    Desai NC; Trivedi AR; Khedkar VM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
    Kumar M; Vijayakrishnan R; Subba Rao G
    Mol Divers; 2010 Aug; 14(3):595-604. PubMed ID: 19697148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
    El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
    Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel inhibitors targeting the Mycobacterium tuberculosis O-acetylserine sulfhydrylase (CysK1) using virtual high-throughput screening.
    Jean Kumar VU; Poyraz Ö; Saxena S; Schnell R; Yogeeswari P; Schneider G; Sriram D
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1182-6. PubMed ID: 23391589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
    Raju A; Kulkarni S; Ray MK; Rajan MG; Degani MS
    Int J Mycobacteriol; 2015 Jun; 4(2):97-103. PubMed ID: 26972877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.
    Hajian B; Scocchera E; Shoen C; Krucinska J; Viswanathan K; G-Dayanandan N; Erlandsen H; Estrada A; Mikušová K; Korduláková J; Cynamon M; Wright D
    Cell Chem Biol; 2019 Jun; 26(6):781-791.e6. PubMed ID: 30930162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid.
    Argyrou A; Vetting MW; Aladegbami B; Blanchard JS
    Nat Struct Mol Biol; 2006 May; 13(5):408-13. PubMed ID: 16648861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis.
    Anthony KG; Strych U; Yeung KR; Shoen CS; Perez O; Krause KL; Cynamon MH; Aristoff PA; Koski RA
    PLoS One; 2011; 6(5):e20374. PubMed ID: 21637807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes.
    Johnson EO; LaVerriere E; Office E; Stanley M; Meyer E; Kawate T; Gomez JE; Audette RE; Bandyopadhyay N; Betancourt N; Delano K; Da Silva I; Davis J; Gallo C; Gardner M; Golas AJ; Guinn KM; Kennedy S; Korn R; McConnell JA; Moss CE; Murphy KC; Nietupski RM; Papavinasasundaram KG; Pinkham JT; Pino PA; Proulx MK; Ruecker N; Song N; Thompson M; Trujillo C; Wakabayashi S; Wallach JB; Watson C; Ioerger TR; Lander ES; Hubbard BK; Serrano-Wu MH; Ehrt S; Fitzgerald M; Rubin EJ; Sassetti CM; Schnappinger D; Hung DT
    Nature; 2019 Jul; 571(7763):72-78. PubMed ID: 31217586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.